Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and serotonin, promising fewer side effects.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
